GLP-(Orforglipron) Tablets

Description

Orforglipron (Non-Peptide GLP-1 Receptor Agonist / Incretin Pathway Modulator)

Form: Tablet
Concentration: 6/12 mg per tablet
Quantity per Bottle: 30 tablets

Molecular Formula: C₅₉H₅₅F₄N₁₀O₆
Molecular Weight: 1,061.14 g/mol
CAS Number: 2381089-83-2
Purity: ≥98% (HPLC)
Storage: Store in a cool, dry place away from light and moisture.

Description

Orforglipron is a first-in-class, non-peptide small-molecule GLP-1 receptor agonist that mimics the action of glucagon-like peptide-1 (GLP-1) through selective receptor activation without requiring peptide-based delivery.
Unlike traditional peptide agonists such as Semaglutide or Tirzepatide, Orforglipron is fully orally bioavailable and exhibits long plasma half-life and metabolic stability.

Preclinical data show that Orforglipron enhances insulin secretion, reduces glucagon output, and slows gastric emptying, resulting in improved glucose control and reduced adiposity.
It is used in research to explore incretin receptor pharmacodynamics, energy expenditure, and metabolic pathway modulation via non-peptide mechanisms.

Orforglipron’s design enables detailed investigation into oral incretin mimetics, offering a platform for understanding GPCR activation, cAMP signaling, and metabolic adaptation in energy balance studies.

Intended Use

This product is intended for laboratory research use only.
It is not for human consumption, diagnostic, or therapeutic applications.
All handling should be performed by qualified professionals in a controlled research environment.

Key Research Applications

• Investigation of non-peptide GLP-1 receptor agonism and incretin signaling

• Studies on glucose metabolism, insulin sensitivity, and body-weight regulation

• Research on GPCR activation and downstream cAMP-mediated pathways

• Analysis of orally bioavailable metabolic modulators and incretin mimetics